PTEN mutant NSCLC require ATM to suppress pro-apoptotic signalling and evade radiotherapy
暂无分享,去创建一个
M. Flentje | B. Polat | C. Münch | Kevin Klann | M. Diefenbacher | O. Hartmann | M. Rosenfeldt | Christina Schülein-Völk | Cristian Prieto-Garcia | Michaela Reissland | Thomas Fischer | E. Gerhard-Hartmann
[1] F. Bassermann,et al. Implementation of CRISPR/Cas9 Genome Editing to Generate Murine Lung Cancer Models That Depict the Mutational Landscape of Human Disease , 2021, Frontiers in Cell and Developmental Biology.
[2] Diane D. Liu,et al. STK11/LKB1 Mutations in NSCLC Are Associated with KEAP1/NRF2-Dependent Radiotherapy Resistance Targetable by Glutaminase Inhibition , 2020, Clinical Cancer Research.
[3] B. Győrffy,et al. Pancancer survival analysis of cancer hallmark genes , 2020, Scientific Reports.
[4] T. Brummer,et al. Immune modulatory effects of oncogenic KRAS in cancer , 2020, Nature Communications.
[5] O. Frings,et al. PTEN and DNA-PK determine sensitivity and recovery in response to WEE1 inhibition in human breast cancer , 2020, eLife.
[6] C. Belka,et al. Pattern-of-failure and salvage treatment analysis after chemoradiotherapy for inoperable stage III non-small cell lung cancer , 2020, Radiation oncology.
[7] P. Zhou,et al. DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer , 2020, Signal Transduction and Targeted Therapy.
[8] J. Squire,et al. Emerging role of PTEN loss in evasion of the immune response to tumours , 2020, British Journal of Cancer.
[9] A. Orian,et al. Maintaining protein stability of ∆Np63 via USP28 is required by squamous cancer cells , 2020, EMBO molecular medicine.
[10] B. Perillo,et al. ROS in cancer therapy: the bright side of the moon , 2020, Experimental & Molecular Medicine.
[11] J. Szustakowski,et al. STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort , 2020, ESMO Open.
[12] Min H. Kang,et al. DNA-PK as an Emerging Therapeutic Target in Cancer , 2019, Front. Oncol..
[13] M. Fanciulli,et al. PTEN as a Prognostic/Predictive Biomarker in Cancer: An Unfulfilled Promise? , 2019, Cancers.
[14] T. Fenton,et al. Inhibition of Nuclear PTEN Tyrosine Phosphorylation Enhances Glioma Radiation Sensitivity through Attenuated DNA Repair. , 2019, Cancer cell.
[15] A. Snijders,et al. LUBAC determines chemotherapy resistance in squamous cell lung cancer , 2019, The Journal of experimental medicine.
[16] D M Parkin,et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods , 2018, International journal of cancer.
[17] Lei-lei Huang,et al. PTEN inhibits non-small cell lung cancer cell growth by promoting G0/G1 arrest and cell apoptosis. , 2018, Oncology letters.
[18] S. Ramalingam,et al. Personalized therapy for lung cancer: striking a moving target. , 2018, JCI insight.
[19] M. Smolka,et al. ATR-mediated proteome remodeling is a major determinant of homologous recombination capacity in cancer cells , 2018, Nucleic acids research.
[20] B. Stiles,et al. PTEN: Tumor Suppressor and Metabolic Regulator , 2018, Front. Endocrinol..
[21] H. Cohen,et al. Time‐to‐Treatment‐Failure and Related Outcomes Among 1000+ Advanced Non–Small Cell Lung Cancer Patients: Comparisons Between Older Versus Younger Patients (Alliance A151711) , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[22] P. Pandolfi,et al. The functions and regulation of the PTEN tumour suppressor: new modes and prospects , 2018, Nature Reviews Molecular Cell Biology.
[23] Zhu Yuan,et al. ATM inhibition induces synthetic lethality and enhances sensitivity of PTEN‐deficient breast cancer cells to cisplatin , 2018, Experimental cell research.
[24] V. Jendrossek,et al. New Insights into Protein Kinase B/Akt Signaling: Role of Localized Akt Activation and Compartment-Specific Target Proteins for the Cellular Radiation Response , 2018, Cancers.
[25] J. Coon,et al. ATM directs DNA damage responses and proteostasis via genetically separable pathways , 2018, Science Signaling.
[26] D. Rickman,et al. Association with Aurora-A Controls N-MYC-Dependent Promoter Escape and Pause Release of RNA Polymerase II during the Cell Cycle , 2017, Cell reports.
[27] W. Shen,et al. PTEN in the maintenance of genome integrity: From DNA replication to chromosome segregation , 2017, BioEssays : news and reviews in molecular, cellular and developmental biology.
[28] E. Yang,et al. The Impact of DNA Repair Pathways in Cancer Biology and Therapy , 2017, Cancers.
[29] A. Asaithamby,et al. Repurposing DNA repair factors to eradicate tumor cells upon radiotherapy. , 2017, Translational cancer research.
[30] R. Mak,et al. Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway. , 2017, Cancer research.
[31] O. Sansom,et al. PTEN deficiency permits the formation of pancreatic cancer in the absence of autophagy , 2017, Cell Death and Differentiation.
[32] P. V. Van Schil,et al. Management of stage I and II nonsmall cell lung cancer , 2017, European Respiratory Journal.
[33] X. Chen,et al. PTEN expression is a prognostic marker for patients with non-small cell lung cancer: a systematic review and meta-analysis of the literature , 2016, Oncotarget.
[34] Lukas E. Dow,et al. Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas , 2016, Proceedings of the National Academy of Sciences.
[35] R. Ortíz-López,et al. Ionizing radiation-induced DNA injury and damage detection in patients with breast cancer , 2015, Genetics and molecular biology.
[36] R. Kennedy,et al. Mechanistic Rationale to Target PTEN-Deficient Tumor Cells with Inhibitors of the DNA Damage Response Kinase ATM. , 2015, Cancer research.
[37] A. Khanna. DNA damage in cancer therapeutics: a boon or a curse? , 2015, Cancer research.
[38] Michael J. Schell,et al. Regulation of the DNA damage response by ubiquitin conjugation , 2015, Front. Genet..
[39] M. Milella,et al. PTEN: Multiple Functions in Human Malignant Tumors , 2015, Front. Oncol..
[40] Y. Zeng,et al. ATM-mediated PTEN phosphorylation promotes PTEN nuclear translocation and autophagy in response to DNA-damaging agents in cancer cells , 2015, Autophagy.
[41] William B. Langdon,et al. Performance of genetic programming optimised Bowtie2 on genome comparison and analytic testing (GCAT) benchmarks , 2015, BioData Mining.
[42] A. Moreira,et al. Personalized therapy for lung cancer. , 2014, Chest.
[43] Yong Li,et al. PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways , 2014, Cell Death and Disease.
[44] Yuxin Yin,et al. PTEN interacts with histone H1 and controls chromatin condensation. , 2014, Cell reports.
[45] Steven J. M. Jones,et al. Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.
[46] C. Furdui. Ionizing radiation: mechanisms and therapeutics. , 2014, Antioxidants & redox signaling.
[47] Edward L. Huttlin,et al. MultiNotch MS3 Enables Accurate, Sensitive, and Multiplexed Detection of Differential Expression across Cancer Cell Line Proteomes , 2014, Analytical chemistry.
[48] Tingting Gu,et al. PTEN C-terminal deletion causes genomic instability and tumor development. , 2014, Cell reports.
[49] L. Zou,et al. DNA damage sensing by the ATM and ATR kinases. , 2013, Cold Spring Harbor perspectives in biology.
[50] Joshua M. Stuart,et al. The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.
[51] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.
[52] Anushya Muruganujan,et al. PANTHER in 2013: modeling the evolution of gene function, and other gene attributes, in the context of phylogenetic trees , 2012, Nucleic Acids Res..
[53] Steven J. M. Jones,et al. Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.
[54] K. Rapti,et al. Quantification of AAV particle titers by infrared fluorescence scanning of coomassie-stained sodium dodecyl sulfate-polyacrylamide gels. , 2012, Human gene therapy methods.
[55] R. Medema,et al. Checkpoint control and cancer , 2012, Oncogene.
[56] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[57] J. Flickinger,et al. Failure rates and patterns of recurrence in patients with resected N1 non-small-cell lung cancer. , 2011, International journal of radiation oncology, biology, physics.
[58] S. Salzberg,et al. TopHat-Fusion: an algorithm for discovery of novel fusion transcripts , 2011, Genome Biology.
[59] Pier Paolo Pandolfi,et al. Nuclear PTEN Regulates the APC-CDH1 Tumor-Suppressive Complex in a Phosphatase-Independent Manner , 2011, Cell.
[60] S. Dry,et al. PTEN loss accelerates KrasG12D-induced pancreatic cancer development. , 2010, Cancer research.
[61] Paul S Mischel,et al. The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation , 2010, Proceedings of the National Academy of Sciences.
[62] Mark D. Robinson,et al. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..
[63] Giuseppe Lippi,et al. Governance of preanalytical variability: travelling the right path to the bright side of the moon? , 2009, Clinica chimica acta; international journal of clinical chemistry.
[64] M. McVey,et al. MMEJ repair of double-strand breaks (director's cut): deleted sequences and alternative endings. , 2008, Trends in genetics : TIG.
[65] K. Shokat,et al. PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML , 2008, Leukemia.
[66] Hong Wu,et al. Pten inactivation accelerates oncogenic K-ras-initiated tumorigenesis in a mouse model of lung cancer. , 2008, Cancer research.
[67] H. Satoh,et al. Regulation of Reactive Oxygen Species by Atm Is Essential for Proper Response to DNA Double-Strand Breaks in Lymphocytes1 , 2007, The Journal of Immunology.
[68] So-Young Rah,et al. Doxorubicin-induced reactive oxygen species generation and intracellular Ca2+increase are reciprocally modulated in rat cardiomyocytes , 2006, Experimental & Molecular Medicine.
[69] S. Tribius,et al. ATM protein expression correlates with radioresistance in primary glioblastoma cells in culture. , 2001, International journal of radiation oncology, biology, physics.
[70] Y Taya,et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. , 1998, Science.
[71] A. Jemal,et al. Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.
[72] G. Mills,et al. A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition. , 2014, Cancer research.